Literature DB >> 35679521

Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience.

Samantha J Seitter1, Paul H McClelland1, Mark A Ahlman2, Stephanie L Goff1, James C Yang1, Lori McIntyre1, Steven A Rosenberg1, James N Kochenderfer1, Jennifer N Brudno1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35679521      PMCID： PMC9548479          DOI： 10.1080/10428194.2022.2076853

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  17 in total

1.  CAR19/22 T cell therapy in adult refractory Burkitt's lymphoma.

Authors:  Xiaoxi Zhou; Tong Ge; Tongjuan Li; Liang Huang; Yang Cao; Yi Xiao; Miao Zhen; Liting Chen; Jianfeng Zhou
Journal:  Cancer Immunol Immunother       Date:  2021-01-18       Impact factor: 6.968

2.  Tisagenlecleucel in Diffuse Large B-Cell Lymphoma. Reply.

Authors:  Stephen J Schuster
Journal:  N Engl J Med       Date:  2019-04-18       Impact factor: 91.245

3.  CAR T cells induce a complete response in refractory Burkitt Lymphoma.

Authors:  Abraham Avigdor; Roni Shouval; Elad Jacoby; Tima Davidson; Avichai Shimoni; Michal Besser; Arnon Nagler
Journal:  Bone Marrow Transplant       Date:  2018-05-24       Impact factor: 5.483

4.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Authors:  Jeremy S Abramson; M Lia Palomba; Leo I Gordon; Matthew A Lunning; Michael Wang; Jon Arnason; Amitkumar Mehta; Enkhtsetseg Purev; David G Maloney; Charalambos Andreadis; Alison Sehgal; Scott R Solomon; Nilanjan Ghosh; Tina M Albertson; Jacob Garcia; Ana Kostic; Mary Mallaney; Ken Ogasawara; Kathryn Newhall; Yeonhee Kim; Daniel Li; Tanya Siddiqi
Journal:  Lancet       Date:  2020-09-01       Impact factor: 79.321

5.  Approach to the Diagnosis and Treatment of Adult Burkitt's Lymphoma.

Authors:  Kieron Dunleavy
Journal:  J Oncol Pract       Date:  2018-11       Impact factor: 3.840

6.  Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells.

Authors:  Wenqun Zhang; Jing Yang; Chunju Zhou; Bo Hu; Ling Jin; Biping Deng; Yang Liu; Shan Wang; Alex H Chang; Juan Du; Zifen Gao; Yonghong Zhang
Journal:  Blood       Date:  2020-06-25       Impact factor: 22.113

7.  Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.

Authors:  Nicholas J Short; Hagop M Kantarjian; Heidi Ko; Joseph D Khoury; Farhad Ravandi; Deborah A Thomas; Guillermo Garcia-Manero; Maria Khouri; Jorge E Cortes; William G Wierda; Srdan Verstovsek; Zeev Estrov; Alessandra Ferrajoli; Philip A Thompson; Sherry Pierce; Susan M O'Brien; Elias Jabbour
Journal:  Am J Hematol       Date:  2017-04-18       Impact factor: 10.047

8.  Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

Authors:  James N Kochenderfer; Robert P T Somerville; Tangying Lu; Victoria Shi; Adrian Bot; John Rossi; Allen Xue; Stephanie L Goff; James C Yang; Richard M Sherry; Christopher A Klebanoff; Udai S Kammula; Marika Sherman; Arianne Perez; Constance M Yuan; Tatyana Feldman; Jonathan W Friedberg; Mark J Roschewski; Steven A Feldman; Lori McIntyre; Mary Ann Toomey; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

9.  Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.

Authors:  Tianyi Wang; Mingxuan Feng; Chengjuan Luo; Xinyu Wan; Ci Pan; Jingyan Tang; Feng Xue; Minzhi Yin; Dongqing Lu; Qiang Xia; Benshang Li; Jing Chen
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

10.  Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma.

Authors:  Ying Liu; Biping Deng; Bo Hu; Wenqun Zhang; Qing Zhu; Yang Liu; Shan Wang; Pei Zhang; Ying Yang; Junhan Yang; Qinlong Zheng; Xinjian Yu; Zifen Gao; Chunju Zhou; Wei Han; Jing Yang; Ling Jin; Chunrong Tong; Alex H Chang; Yonghong Zhang
Journal:  Blood Adv       Date:  2022-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.